Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals

Executive Summary

A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.

Advertisement

Related Content

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018
Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition
Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal
Cipla Acquires Avenue, Primes Play In Pain Amid US Opioid Crisis
Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Newly Hatched Mirum To Focus On Rare Liver Disease Candidates Shelved By Shire
Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital
Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'
Boston Bags Assets From GSK and Novartis

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel